^
    Back
    Association details:
    Biomarker:SLC8A1-ALK fusion
    Cancer:Lung Adenocarcinoma
    Drug:Zykadia (ceritinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Medicine (Baltimore)
    Title:

    Excellent response of lung adenocarcinoma harboring a rare SLC8A1 downstream intergenic region ALK fusion to ceritinib treatment: A case report

    Published date:
    08/26/2022
    Excerpt:
    ...the patient was diagnosed with "stage IV lung adenocarcinoma"…A rare solute carrier family 8 member A1 (SLC8A1) downstream intergenic region ALK fusion was identified in biopsy specimens using next-generation sequencing (NGS)….The patient received first-line molecular-targeted therapy (ceritinib)....After nearly 9 months, the best evaluation of partial remission (PR) was obtained.
    DOI:
    10.1097/MD.0000000000030255